Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
Standard
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. / Kaufmann, Manfred; Hortobagyi, Gabriel N; Goldhirsch, Aron; Scholl, Suzy; Makris, Andreas; Valagussa, Pinuccia; Blohmer, Jens-Uwe; Eiermann, Wolfgang; Jackesz, Raimund; Jonat, Walter; Lebeau, Annette; Loibl, Sibylle; Miller, William; Seeber, Sigfried; Semiglazov, Vladimir; Smith, Roy; Souchon, Rainer; Stearns, Vered; Untch, Michael; von Minckwitz, Gunter.
in: J CLIN ONCOL, Jahrgang 24, Nr. 12, 12, 2006, S. 1940-1949.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
AU - Kaufmann, Manfred
AU - Hortobagyi, Gabriel N
AU - Goldhirsch, Aron
AU - Scholl, Suzy
AU - Makris, Andreas
AU - Valagussa, Pinuccia
AU - Blohmer, Jens-Uwe
AU - Eiermann, Wolfgang
AU - Jackesz, Raimund
AU - Jonat, Walter
AU - Lebeau, Annette
AU - Loibl, Sibylle
AU - Miller, William
AU - Seeber, Sigfried
AU - Semiglazov, Vladimir
AU - Smith, Roy
AU - Souchon, Rainer
AU - Stearns, Vered
AU - Untch, Michael
AU - von Minckwitz, Gunter
PY - 2006
Y1 - 2006
N2 - Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.
AB - Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.
M3 - SCORING: Zeitschriftenaufsatz
VL - 24
SP - 1940
EP - 1949
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 12
M1 - 12
ER -